Altre lingue Golden Biotechnology Corporation

Azioni

4132

TW0004132006

Prezzo di chiusura Taipei Exchange Altri mercati azionari 00:00:00 25/06/2024			Variaz. 5gg	Var. 1 gen.
22,95 ^TWD	+4,56%		-1,29%	-41,53%

29/04	Golden Biotechnology Corporation riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
18/01	Golden Biotechnology Corp. svela i risultati del suo studio clinico di Fase II che studia l'Antrochinonolo	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	29/04
ASCO GI 2024, Golden Biotech's Antroquinonol Shows Significantly Prolonged Survival in Untreated Metastatic Pancreatic Cancer Patients	19/01
Golden Biotechnology Corp. Unveils the Findings of Its Phase II Clinical Trial Investigating Antroquinonol	18/01
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	14/08/23
Golden Biotech Announces Positive Results with Longer Survival Compared with Standard Treatments from Interim Analysis of Phase 2 Trial for Antroquinonol as 1st Line Treatment for Stage 4 Metastatic Pancreatic Cancer	05/05/23
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	28/04/23
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2022	12/08/22
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	28/04/22
Golden Biotechnology Corporation Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients	07/01/22
Golden Biotechnology Corporation Receives Antroquinonol Oral Covid-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe Covid-19 Patients	16/09/21
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2021	16/08/21
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	30/03/21
GoldenBiotech's New Drug Antroquinonol Trial Receives Positive Response from DMC Review and Licenses for 4 Countries	04/02/21
Golden Biotechnology Corp. Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia	26/11/20
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2020	11/08/20
Anti-viral and Anti-Inflammatory Response: GoldenBiotech's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA	02/07/20
Golden Biotechnology Corp. Announces it's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA	01/07/20
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2019	05/04/20
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2019	06/08/19
Golden Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2018	02/04/19

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Golden Biotechnology Corporation

Azioni

4132

TW0004132006

Altre lingue

Filtri